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Abstract 
High endothelial venules (HEVs) are structurally distinct blood vessels that develop 
during embryonic and neonatal life in all secondary lymphoid organs except the 
spleen. HEVs are critical for initiating and maintaining immune responses because 
they extract naïve and memory lymphocytes from the bloodstream, regardless of 
antigen receptor specificity, and deliver them to antigen-presenting cells inside lymph 
nodes under homeostatic conditions. HEVs also develop post-natally in non-
lymphoid organs during chronic inflammation driven by autoimmunity, infection, 
allografts and cancer. Extranodal HEVs are usually surrounded by dense 
lymphocytic infiltrates organised into lymph-node like, T- and B-cell rich areas called 
tertiary lymphoid structures (TLS). HEV neogenesis is thought to facilitate the 
generation of tissue-destroying lymphocytes inside chronically inflamed tissues and 
cancers. 
We are studying the mechanisms underpinning HEV neogenesis in solid cancers 
and the role of homeostatic T cell trafficking in controlling cancer immunity. In this 
chapter we describe methods for identifying HEV in tissue sections of cancerous 
tissues in humans and mice using immunohistochemical staining for the HEV-
specific marker peripheral lymph node addressin (PNAd). L-selectin binding to PNAd 
is a necessary first step in homeostatic lymphocyte trafficking which is the defining 
function of HEV. We also describe methods to measure L-selectin dependent 
homing of lymphocytes from the bloodstream into lymphoid tissues and tumours in 
preclinical cancer models.  
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1. Introduction  
High endothelial venules (HEVs) are structurally and antigenically distinct blood 
vessels especially adapted for lymphocyte trafficking (1). HEV develop in every 
secondary lymphoid organ except the spleen (i.e. lymph nodes (LN), tonsils and 
Peyer’s patches) during embryonic and neonatal life, and are fully integrated into the 
blood vasculature supplying these organs. The endothelial cells (EC) lining HEV in 
neonatal mice are immature and express the vascular addressin, Mucosal Addressin 
Cell Adhesion Molecule (MAdCAM)-1. During the first weeks of neonatal life, HEV 
mature into Peripheral Node Addressin (PNAd) expressing HEV (2). PNAd 
expression is induced by gut-derived dendritic cells in neonates (3) and maintained 
by Lymphotoxin-β receptor (LTβR) signalling in HEV EC stimulated by LTαβ 
expressing dendritic cells and lymphocytes (4, 5). HEV play a critical role in 
delivering naïve and memory T and B lymphocytes, regardless of antigen receptor 
specificity, from the bloodstream into lymphoid organs under homeostatic conditions. 
Here, lymphocytes scan dendritic cells and stromal networks for activating, 
tolerogenic and homeostatic stimuli. HEV, therefore, regulate the outcome of an 
immune response be it activation, tolerance or homeostatic proliferation of 
lymphocytes. PNAd-expressing blood vessels that resemble structurally distinct HEV 
in LN, develop post-natally in non-lymphoid organs during chronic inflammation 
driven by autoimmunity, infection and allografts (6). These extranodal HEV are 
characteristically surrounded by dense lymphocytic infiltrates organised into lymph-
node like structures with discrete T and B-cell rich areas and germinal centres and 
are called tertiary lymphoid structures (TLS). Extranodal HEV facilitate entry of blood 
borne lymphocytes and are therefore, critical to the development and immune 
function of TLS. HEV-containing TLS also develop in solid, vascularised cancers and 
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are receiving increasing attention because of their potential role in regulating 
immunity at the tumor site (7, 8). The presence of TLS in resected solid cancers has 
been correlated with prolonged patient outcome in some cancers such as breast 
cancer (9, 10), melanoma (11, 12) and lung cancer (13). In other cancers, TLS have 
been shown to either promote carcinogenesis such as virus-associated 
hepatocellular carcinoma (14), or to accumulate with disease progression such as in 
primary breast carcinoma (15). In colorectal cancer, TLS often containing germinal 
centres (Crohn’s-like aggregates), develop in the surrounding peritumoural stroma 
as well as inside cancerous tissue. The number of TLS in colorectal cancer has been 
reported to correlate either with improved patient outcome or with disease 
progression depending on the stage of the disease (16-19).  
In breast cancer and melanoma, the density of HEV correlated with improved patient 
outcome highlighting the important role that HEV play in orchestrating anti-cancer 
immunity (20, 21). HEV neogenesis correlates with regression of established 
tumours in preclinical mouse tumour immunotherapy models, such as depletion of 
Foxp3+ regulatory T cells (22, 23) or combined checkpoint blockade inhibition and 
angiogenesis therapy (24). HEV neogenesis and tumour regression are also seen 
when the TNF superfamily member LIGHT (TNSF14) (which signals via LTβR, an 
important driver of lymphoid organ development) is expressed by tumour cells or 
targeted to tumours or tumour blood vessels (25-27). It is thought that the anti-
tumour effects are due to the generation of cancer cell-destroying lymphocytes from 
naïve T cells which have been recruited from the bloodstream into the cancer by 
newly formed HEV.  
PNAd-expressing blood vessels lined by flat endothelial cells, rather than the 
cuboidal or plump endothelial morphology typical of mature HEV, are found inside 
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cancer-induced ectopic lymphoid aggregates that are not organised into distinct T/B 
cell areas (28). These could represent immature HEV-containing structures in the 
process of forming TLS, or de-differentiating HEV as found in reactive LN or 
following disruption of the LN microenvironment (5, 29). Interestingly, PNAd-
expressing blood vessels that form following depletion of Foxp3+ regulatory T cells 
from methylcholanthrene induced tumour-bearing mice are not generally associated 
with histologically distinct, TLS (22) which suggests that HEV neogenesis may occur 
independently of lymphoid neo-organogenesis. The development of HEV in the 
absence of full-blown TLS correlates with T cell infiltration and cancer regression in 
this experimental model, highlighting the important role of HEV in controlling anti-
tumoural immunity. 
PNAd expressing blood vessels have been reported in preclinical mouse tumour 
models particularly following immunotherapy, In tumour cell transplant models, PNAd 
expression is induced on tumour blood vessels by infiltrating CD8+ T cells and NK 
cells (30). In marked contrast to HEV development in LN, PNAd expression is not 
dependent on LTβR signaling but is stimulated instead by Lymphotoxin α3 (LTα3). 
Although comprising <10% of the tumour vascular network and lined by flat 
endothelial cells PNAd-expressing tumour blood vessels are functional in that they 
recruit naïve, L-selectin expressing T cells from the bloodstream into the tumour 
where they are activated to kill tumour tissue (30). In methylcholanthrene-induced 
fibrosarcomas in mice, HEV neogenesis is also not dependent on LTβR but is driven 
mainly by T cell-derived TNF-α and LTα3 (23). However, HEV neogenesis during 
anti-angiogenic/anti-PD-L1 therapy is dependent on LTβR signalling and in poorly 
infiltrated tumours where HEV neogenesis is low, such as glioblastomas, the 
combination of agonistic antibodies to LTβR alongside anti-angiogenic/anti-PD-L1 
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therapy boosts HEV neogenesis (22). Together, these findings suggest that TNFR 
and/or LTβR signaling in endothelial cells stimulates the development of PNAd 
expressing, HEV blood vessels that promote anti-tumour immunity by recruiting 
naïve T cells into cancerous tissues.  
We are studying the role of homeostatic T cell trafficking via HEV and the 
mechanisms underpinning HEV neogenesis in controlling local immunity inside 
mouse tumours and human cancers. We use immunohistochemistry to identify HEV 
in clinical and murine tissues by detection of PNAd, a specific marker of HEV 
(Figure 1). We measure L-selectin-dependent recruitment of naïve T lymphocytes 
from the bloodstream into tissues, via PNAd-expressing HEV, in mice using short-
term homing assays and analyse tissue-infiltrating T cells by flow cytometry (Figure 
2) (31-33) and immunohistochemistry to co-locate infiltrating T cells and HEV 
(Figure 3) (31, 34).   
 
2. Materials 
All reagents which are not commercially available should be prepared with 
deionised, sterile water. All reagents stored at +4oC unless otherwise specified by 
the manufacturer. Tissues should be collected into sterile phosphate buffered saline, 
lymphocytes isolated in growth media and resuspended in saline for injection into 
mice.  All procedures apart from tissue collection and injections into mice should be 
performed in a biological safety cabinet. The following reagents are used in all 
methods: calcium- and magnesium-free phosphate-buffered saline (PBS), complete 
RPMI 1640 growth media supplemented with penicillin and streptomycin (RPMI), 
heat-inactivated (30 min at 56oC) foetal calf serum (FCS), 70% alcohol for 
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sterilisation. The antibodies used for immunofluorescence staining of frozen or 
paraffin-embedded tissue sections and flow cytometry of T cells are listed in Table 1. 
 
2.1 Immunolabelling HEV and TLS in murine tumour cryosections 
1. Tissue-Tek plastic base molds (Thermo Fisher Scientific). 
2. Optimum cutting temperature (OCT) compound. 
3. Dry ice with or without ethanol for snap freezing murine tissue in OCT. 
4. Cryostat capable of cutting cryosections. 
5. Hydrophobic pen for creating a hydrophobic barrier around tissue section (e.g. 
Pap pen, Vector). 
6. Humidified chamber containing wet paper towel to prevent evaporation of 
staining reagents. 
7. PBS for washing steps. 
8. Fixative of choice (see Note 1). For example: 
a. Acetone stored in glass Pyrex bottle at -20oC. 
b. Fresh 4% formaldehyde.  Dilute 16% formaldehyde in PBS and adjust 
pH to 7.4; 16% formaldehyde can either be bought in ampules (Thermo 
Fisher Scientific) or prepared from paraformaldehyde powder (Sigma) 
and stored at -20oC. Limit exposure to paraformaldehyde by preparing 
in a fume hood. Store 4% formaldehyde at 4oC and use within 1 week. 
c. Periodate-lysine-paraformaldehyde fixative (PLP; 0.075 M lysine, 0.37 
M sodium phosphate (pH 7.2), 2% formaldehyde, and 0.01 M NaIO4). 
Mix the following to create a buffered lysine solution: 0.36g Lysine 
(Sigma), 7.5 mL NaH2PO4 (0.1M, pH 7.2; Sigma), 2.5 mL Na2HPO4 
9 
 
(0.1M, pH 7.2; Sigma) and 10 mL H2O. Immediately before use, add 15 
mL of the buffered lysine solution to the following: 5 mL 8% 
formaldehyde and 50 mg Sodium meta-periodate (NaIO4; Sigma). It is 
not necessary to pH the final solution.  
9.  If using formaldehyde or PLP to fix sections then prepare 0.3 M glycine 
(Thermo Fisher Scientific) in PBS, pH 7.4, to quench free aldehydes.  
10. Optional: Avidin/Biotin blocking kit if a biotinylated primary or secondary 
antibody is used. 
11. Serum blocking solution to block non-specific binding of antibodies. 2.5-5% 
serum of the species in which the secondary antibody is raised is often used. 
Other sera, for example horse or mouse serum,may also be used. 
12. Primary antibodies diluted in 1% Bovine serum albumin (BSA, Sigma) in PBS. 
Rat anti-mouse PNAd antibody (clone MECA-79, rat IgM) is used at a working 
concentration of 2.5 g/mL to detect HEV (see Notes 2 and 3). Alternatively, 
MECA-79 hybridoma supernatant can be prepared in-house and titrated on 
LN sections before staining HEV in tumour sections. Additional antibodies can 
be used simultaneously to detect other cells or structures such as TLS. 
Example 1: Biotinylated rat anti-mouse pan-EC antigen (clone MECA-32, rat 
IgG2a, used at a working concentration of 2 g/mL, Biolegend) can be used 
to confirm that MECA-79 stains endothelial structures (Figure 1) (see Note 
4). Example 2: Biotinylated rat anti-mouse MAdCAM-1 (clone MECA-367, rat 
IgG2a, used at a working concentration of 2 g/mL, Biolegend) can be used 
to detect immature HEV in tumours (Figure 1). Example 3: The presence of 
TLS in tumour tissue, characterized by T/B cell segregation and follicular 
dendritic cell (FDC) networks may be revealed using antibodies to T cells (e.g. 
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rabbit anti-human CD3, which also detects mouse CD3, DAKO A0452, used 
at 2 g/mL), B cells (biotinylated rat anti-mouse/human CD45R/B220, clone 
RA3-6B2, rat IgG2a, used at a working concentration of 2 g/mL, Biolegend), 
and FDC (rat anti-mouse FDC, clone FDC-M1, rat IgG2c, used at a working 
concentration of 2 g/mL, BD Biosciences). 
13. For every antibody used, an isotype control antibody should be used at the 
same working concentration, in parallel on another section to check the 
staining is specific. A rat IgM isotype control antibody is used to check MECA-
79 staining is specific. Biotinylated rat IgG2a is used to check pan-EC antigen 
(clone MECA-32), MAdCAM-1 (clone MECA-367) and B cell (clone RA3-6B2) 
staining is specific (Figure 1). Rat IgG2c is used to check FDC (clone FDC-
M1) staining is specific and rabbit IgG polyclonal isotype control is used to 
check CD3 (DAKO A0452) staining is specific. 
14. Fluorescently conjugated secondary reagents diluted in 1% BSA in PBS. To 
detect MECA-79, a fluorescently conjugated anti-rat IgM may be used. Other 
primary antibodies can be detected with fluorescently conjugated species-
specific secondary antibodies or fluorescently conjugated streptavidin 
reagents. The fluorochromes chosen should be compatible with the specific 
capabilities of the microscope being used to analyse the tissues i.e. the laser 
systems and detectors. The Alexa Fluor dyes are excellent conjugates since 
they are very bright and resistant to photobleaching; Alexa Fluor 488, 594 and 
647 emission spectrum are sufficiently separated to provide minimal overlap 
between fluorochromes and are compatible with most standard widefield and 
confocal fluorescent microscopes.  
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15. Optional: nuclear counterstain. Example Hoescht or DAPI (Sigma) diluted in 
PBS. 
16.  Mounting media. Example: Vectashield (Vector) or Prolong gold (Thermo 
Fisher Scientific). 
17. Glass coverslips (thickness #1.5 coverslips should be used in fluorescence 
microscopy to obtain the brightest images with minimal spherical aberration; 
Thermo Fisher Scientific). 
 
2. 2 Immunolabelling HEV and TLS in paraffin-embedded murine tumour 
sections 
1. Tissue-Tek plastic base molds (Thermo Fisher Scientific). 
2. Neutral buffered formal saline (NBFS). 
3. Paraffin wax (Shandon Histoplast, Thermo Fisher Scientific). 
4. Microtome capable of cutting paraffin sections (e.g.Thermo Fisher Scientific). 
5. Blades (MX35, Thermo Fisher Scientific). 
6. Hydrophobic pen for creating a hydrophobic barrier around tissue section 
(e.g.Pap pen, Vector). 
7. Humidified chamber containing wet paper towel to prevent evaporation of 
staining reagents. 
8. 100% Xylene. 
9. Graded alcohols: 100%, 95%, 90%, 80% and 70% ethanol. 
10. PBS for washing steps. 
11. Peroxidase blocking solution: either 1% hydrogen peroxide/methanol or a 
commercial blocking reagent (e.g. Bloxall; Vector) (see Note7). 
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12. Serum blocking solution to block non-specific binding of antibodies. Often 2.5-
5% serum of the species in which the secondary antibody is made is used. 
Other sera for example horse or mouse serum may also be used. 
13. Primary antibody diluted in 1% BSA in PBS. Rat anti-mouse PNAd antibody 
(MECA-79, rat IgM, used at a working concentration of 2.5 g/mL) can be 
used to detect HEV. 
14. A rat IgM isotype control antibody should be used at the same working 
concentration in parallel on another section to check MECA-79 staining is 
specific. 
15. Enzyme conjugated secondary antibody complexes to detect primary 
antibody. Example Immpress anti-rat horseradish peroxidase (HRP) kit 
(Vector).  
16. Enzyme substrate to visualize immunolabelled target. Example: DAB, Impact 
VIP or Impact SG (Vector). 
17. Optional: nuclear counterstain. Example: Haematoxylin (Sigma). 
18. Mounting media. Example: distyrene, plastizer and xylene (DPX; Raymond 
Lamb). 
19. Glass coverslips (Menzel; Thermo Fisher Scientific). 
 
2.3 L-selectin dependent homing of naïve T lymphocytes in mice  
1. The following equipment is required: 0.001g balance in animal unit for 
weighing tissues, humidified CO2 incubator at 37oC, refridgerated bench top 
centrifuge, trypan blue solution and Neubauer chamber or other equipment 
for cell counts and viability, 2 mL plastic syringes, 70 Pm cell strainers, 50 mL 
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polypropylene tubes. T cell donor mice: 8-12-week-old, sex-matched and 
syngeneic to experimental mice.  
2. Experimental mice with HEV-containing cancers as recipients of donor T 
cells.  
3. Sterilised instruments (dissecting scissors, forceps and scalpel).  
4. Labelled tubes containing 1 mL ice-cold PBS for collection of spleens from T 
cell donor mice. 
5. Labelled tubes containing 1 mL ice-cold PBS for collection of cancerous 
tissues, lymph nodes and spleens from experimental mice after injection of 
donor T cells (labelled with mouse number (e.g.1-5) and organ (e.g. cancer, 
spleen, LN).    
6. Red blood cell lysis buffer.   
7. Naïve T cell isolation kits using negative selection.  
8. Cell tracker dye: carboxyfluorescein diacetate-succinimidyl ester (CFSE, 
Molecular Probes).  
9. Fluorescently conjugated antibodies to TCR (clone H57-597, Armenian 
hamster IgG), L-selectin/CD62L (clone MEL-14, rat IgG2a) and CD44 (clone 
IM7, rat IgG2b). 
10. Rat-anti mouse PNAd (clone MECA 79, rat IgM), fluorescently conjugated or 
biotinylated anti-rat IgM to detect MECA79 in tissue sections.  
11. Fixative: 2% formaldehyde/5% sucrose in PBS, 20% sucrose in PBS.  
12. Freezing and storing tissues: liquid nitrogen. 
 
3. Methods 
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3.1. Immunolabelling HEV and TLS in murine tumour cryosections 
1. Collect tumour tissue and place immediately in optimal cutting temperature 
compound (OCT) in a plastic mould. Add sufficient OCT to completely cover 
the tissue. 
2. Snap-freeze in dry ice and store blocks in small plastic zip-lock bags at -80oC 
until needed.  
3. Cut 5-10 Pm sections on a cryostat and mount sections on glass slides. 
Typically, we mount 2 sections per slide. 
4. Allow slides to dry for approximately 1 hour at room temperature (RT) and 
store in a slide box at -80oC until needed.  
5. Remove slides from freezer and allow them to warm up to RT and wipe away 
any residual moisture, taking care not to touch the tissue section.  
6. Fix sections in ice-cold 100% acetone, 4% formaldehyde or PLP fixative for 
10 minutes (see Note 1). Wash slides 3 times in PBS over 5 minutes at RT. 
7. Drain slides and carefully wipe off excess liquid before next step. Be careful 
not to let the section dry out. 
8. Draw a circle round each section with a hydrophobic marker. 
9. Optional: if fixed in 4% formaldehyde or PLP quench free aldehydes with 0.3 
M glycine in PBS for 10 min at RT and then wash slides 3 times in PBS over 5 
minutes at RT. 
10. Optional: if using a biotinylated antibody block endogenous biotin with 
avidin/biotin block and then wash slides 3 times in PBS over 5 minutes at RT. 
11. Block non-specific protein binding with serum blocking solution for 30 min at 
RT. 
12. Drain slides (no need to wash the slides). 
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Incubate with MECA-79 antibody or rat IgM isotype control in 1%BSA/PBS 
overnight at 4oC or for 1 hour at RT in a humidified chamber. Optional: 
include other antibodies such as MECA-367 to identify immature HEV, MECA-
32 to confirm that MECA-79 is detected on EC (see Figure 1) or T cell, B cell 
and FDC antibodies (Table 1) to determine if TLS are present. 
13. Wash slides 3 times in PBS over 5 minutes at RT. 
14. Incubate with fluorescently conjugated secondary antibodies in 1% BSA/PBS 
for 30-60 min at RT (see Note 5). Counterstain with nuclear dye for 10 min at 
RT (e.g. Hoescht or DAPI). 
15. Wash slides 3 times in PBS over 5 minutes at RT. 
16. Mount slides in mounting media and coverslip. 
17. Slides should be stored in the dark at +4oC until analysis and image 
acquisition by fluorescence microscopy. Staining may be preserved for at 
least 2 months if Alexa Fluor dyes are used and slides are stored correctly. 
 
 
3.2 Immunolabelling HEV and TLS in paraffin-embedded murine tumour 
sections 
1. Collect tumour tissue and fix in neutral buffered formal saline (NBFS) for 24- 
48 hours. 
2. Process in tissue processor (Leica) as follows: 
• 70% Ethanol - 1 hour at 45oC 
• 80% Ethanol - 1 hour at 45oC 
• 95% Ethanol - 1 hour at 45oC 
• 100% Ethanol – 1 hour at 45oC 
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• 100% Ethanol – 1 hour at 45oC 
• 100% Ethanol – 1 hour at 45oC 
• 100% Xylene – 1.5 hours at 45oC 
• 100% Xylene – 2 hours at 45oC  
• 100% Xylene – 2 hours at 45oC 
• Wax - 1.5 hours at 65oC  
• Wax – 2 hours at 65oC  
• Wax – 2.5 hours at 65oC  
• Embed in wax and cool 
3. Store tissue blocks in a cool dry place until ready to cut. 
4. Pre-cool tissue blocks on ice or on a cold plate (Leica).  
5. Cut 5-10 Pm sections on a microtome and mount on glass slides. 
6. Place slides in a slide rack at 60oC for 1 hour to overnight to melt off wax. 
7. Hydrate sections in a slide chamber with 3X 100% Xylene washes, 5 min 
each and then descending alcohols (100%, 100%, 90% and 70%) for 3 min 
each. Wash in running water for 5 min and then rinse in dH20. 
8. Use either Tris/EDTA (10 mM Tris base, 1 mM EDTA solution, 0.05% Tween 
20, pH 9.0) or Sodium citrate (10 mM Sodium citrate, 0.05% Tween 20, pH 
6.0) antigen retrieval buffer for heat induced epitope retrieval (see Note 6). 
9. Wash slides 3 times in PBS over 5 minutes. 
10. Drain slides and carefully wipe off excess water before next step. Be carefully 
not to let the section dry out. 
11. Draw a circle round each section with a hydrophobic marker. 
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12. Neutralize endogenous peroxidase activity with 1% hydrogen peroxide/ 
methanol for 10 min at RT or alternatively use a commercial blocking reagent 
(e.g.Bloxall, Vector; see Note 7). 
13. Wash slides 3 times in PBS over 5 minutes. 
14. Block non-specific protein binding with blocking solution for 30 min at RT.  
15. Drain slides (no need to wash). 
16. Incubate with MECA-79 antibody or rat IgM isotype control in 1%BSA/PBS 
overnight at 4oC or for 1hour at RT in a humidified chamber. 
17. Wash slides 3 times in PBS over 5 minutes. 
18. Incubate with anti-rat Immpress reagent (Vector) or other HRP or conjugated 
secondary antibody and incubate at RT for 30 min. 
19. Wash slides 3 times in PBS over 5 minutes. 
20. Incubate with freshly prepared DAB Chromogen solution and monitor under a 
microscope until colour develops. 
21. Rinse with deionised H2O and then wash in fresh deionised H2O. 
22. Optional: It is possible to sequentially stain the same tissue section with other 
antibodies in order to identify other cells and structures using different 
coloured chromogens (see Note 8). For example, the presence of TLS 
containing organized B and T cell zones can be verified with rat anti-mouse 
CD45R/B220 (Biolegend) detected with anti-rat Immpress reagent (Vector) 
and Vector-VIP (purple; Vector) followed by rabbit anti-mouse CD3 (DAKO) 
detected with anti-rat Immpress reagent (Vector) and Vector-SG (grey; 
Vector).  
23. Counterstain in Haematoxylin (10-20 secs) and Blue in Scotts tap water (10 
sec) (see Note 9). 
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24. Dehydrate in ascending alcohols (70%, 90% 100% and 100%) for 3 min each 
and 3X 100% Xylene washes for 5 min each. 
25. Mount in mounting media and coverslip. 
 
3.3 L-selectin-dependent homing of naïve T lymphocytes in mice 
1. Cull T cell donor mice by CO2 inhalation and/or cervical dislocation and pin out 
on dissecting board ventral side up. Swab ventral surface with 70% alcohol to 
sterilise and wet fur, open abdominal cavity by midline incision using scalpel.  
Remove spleen carefully using forceps and scissors and avoid damaging the 
surface. Collect spleen into PBS in labelled tubes and transport on ice to 
biological safety cabinet (see Notes 10 and 11).  
2. Place cell strainer in neck of a labelled 50 mL polypropylene tube in a tube 
rack and pour spleen and PBS through cell strainer. 
3. Split open paper covering of 2 mL plastic syringe, remove plunger using paper 
covering to maintain sterility of flat end (not rubber seal end).  Mash spleen 
using flat end of plunger.  Wash strainer using 5 mL of PBS, repeat if 
necessary to completely disaggregate tissue; discard strainer.  
4. Seal tubes and collect splenocytes by centrifugation at 250 g for 5 minutes at 
+4oC.  Aspirate or remove PBS by pouring.  
5. Tap bottom of tube to dislodge cell pellet, carefully resuspend in 2 mL red cell 
lysis buffer using 10 mL strippette, make up to 5 mL with red cell lysis buffer 
and incubate for 5 minutes on ice.  Add 10 mL PBS, collect cells by 
centrifugation and repeat once. 
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6. Isolate naïve T cells by negative selection using commercially available kits 
according to manufacturer’s instructions (see Note 12) 
7. Resuspend T cells to 5 x 107/mL in FCS-free PBS for labelling with CFSE 
(see Note 13) and remove 1 x 105 cells for staining to check naïve T cell 
purity (see Note 14).  
8. Label T cells in 2 µM CFSE in FCS-free PBS in the dark for 15 min at 37oC, 
wash twice in 5-10 mL PBS containing 1% FCS, resuspend to 2.5 x 107 
cells/mL in saline and split into 2 equal aliquots.  Collect cells by centrifugation 
and preincubate one aliquot with 100 µg/mL rat anti-mouse L-selectin (clone 
MEL-14, rat IgG2a) and the second aliquot with 100 µg/mL isotype control 
(clone MAC193, rat IgG2a) for 30 min at 4oC.  
9. Inject 0.2 mL of T cells plus antibody (5 x 106 cells) intravenously into 
experimental mice (see Notes 10, 15 and 16).  
10. Cull mice after 1, 4 or 24 hours (see Note 17) by CO2 inhalation and/or 
cervical dislocation Collect blood by cardiac puncture from the left ventricle 
using a 1 mL syringe with 27G needle into 1.5 mL heparinised tubes 
Eppendorf tubes containing 100 µl of 10 units/mL heparin or citrate-EDTA.  
Store carcasses on ice and prepare for dissection, as described in Step 1.  
11. Collect tumour, spleen, peripheral (axillary, brachial and inguinal) LN and 
mucosal (mesenteric or mediastinal) LN, and process as follows: cut tumour, 
spleen and mucosal LN into two halves, one half to analyse infiltrating T cells 
by histology and the other half to isolate infiltrating T cells for flow cytometric 
analysis. Pool right peripheral LN and use to isolate infiltrating T cells. Collect 
left axillary, brachial and inguinal LN separately for immunolocalisation of 
infiltrating T cells. Fix LN, spleen and tumour in 2% formaldehyde/5% sucrose 
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in PBS for 2 hours, transfer to 20% sucrose in PBS for 2 hours, snap freeze in 
liquid nitrogen, and store at -80°C for up to 2 years. Collect lymphocytes from 
one half of a tumour, one half of spleen and pooled right peripheral LN, as 
described in Steps 2-5 above (see Notes 18 and 19).  
12. Lyse red blood cells in spleen, tumour and peripheral blood, as described in 
Step 5.   
13. Analyse CFSE-labeled lymphocytes on a flow cytometer analyzer using the 
ﬂuorescein isothiocyanate ﬁlter. Data on 2 x 105 viable cells in spleen and 
blood, and 5-10 x 105 viable cells for LN is acquired and the data analyzed 
using FlowJo software. The percentage of CFSE-labeled cells recovered in 
the spleen, blood, and each group of LN is determined and compared 
between control and treated animals.  If L-selectin deficient T cells are 
available label using CMTMR, mix them 1:1 with CFSE labelled L-selectin 
sufficient T cells and inject a total of 20 x 106 cells into a single group of 
experimental mice. In tissues with functional HEV, L-selectin sufficient T cells 
are highly enriched over L-selectin deficient T cells (Figure 2).  
14. Cryostat sections of 8 µm are cut from fixed, frozen tissues (see Step 11), 
HEV stained using MECA-79 and red fluorescence–conjugated secondary 
antibody, as described in Section 3.1, Step 12 but without additional fixation. 
The presence of TLS in fixed tumour tissue may be revealed using antibodies 
that detect T and B cells in formalin-fixed paraffin embedded tissues (Table 
1). The position of CFSE-labeled lymphocytes (green) in relation to HEVs 
(red) is determined by ﬂuorescence microscopy using a confocal laser 
scanning microscope. For each tissue, 10 to 15 images containing complete 
cross-sections through 30 to 55 HEVs (average total HEV area 2500 m2) are 
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collected and analyzed using Image J-NIH software. The total cross-sectional 
area of HEVs and the remaining area within each image are calculated. 
CFSE-labeled cells “inside HEVs” are those attached to the luminal surface of 
the vessel wall and within the HEV wall (Figure 3A; arrows). The remaining 
CFSE-labeled cells are scored as “outside HEVs” (Figure 3A; arrowheads). 
Total numbers of lymphocytes counted ranged from 200-500 cells. The 
numbers of CFSE-labeled cells inside and outside HEVs are not signiﬁcantly 
different in inguinal and brachial LN of individual mice or between animals in 
the same experimental group (31). Results are pooled from inguinal and 
brachial LN of mice within each experimental group and, where the results 
were similar, between experimental groups and are expressed as means ± 
SEM CFSE-labeled cells/mm2 inside and outside HEVs (34).  
 
4. Notes 
1. Fixation is required to maintain tissue morphology. The choice of fixative 
depends on the antigen and antibody used to detect it. Formaldehyde is a 
cross-linking fixative and maintains good tissue architecture however, 
some antigens cannot easily be detected after formaldehyde fixation (e.g. 
mouse CD4). Acetone removes lipids, dehydrates cells and precipitates 
proteins so cell structure is poorly preserved but may allow better 
detection of some antigens (e.g. mouse CD4). PLP can be prepared with 
varying concentrations of formaldehyde and was designed to primarily 
cross-link carbohydrates to main antigenic sites on proteins. Since 
membranes are rich in glycoproteins and glycolipids, PLP provides good 
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preservation of membrane antigens of the immune system. HEV are 
detected well with all of these fixation methods, however if other cells of 
the immune system are also immunolabelled then different fixation 
protocols should be tested.  
2. MECA-79 is a rat IgM and can precipitate over time resulting in speckly 
staining at which point the antibody needs to be discarded. 
3. MECA-79 can detect HEV in both mouse and human cryosections or 
paraffin sections. However other antibodies e.g. clones MECA-32 and 
MECA-367 are mouse specific so alternative human specific antibodies 
would be needed. 
4. When two rat primary antibodies are used simultaneously (e.g. clones 
MECA-79 and MECA-367 or MECA-32) fluorescently or biotin conjugated 
primary antibodies or isotype specific secondary antibodies should be 
used so that anti-rat secondaries are avoided. 
5. Since MECA-79 is a rat IgM antibody, it can be detected with an anti-rat 
IgM secondary antibody. However this secondary antibody will cross-react 
to endogenous mouse IgM, which can be detected in plasma cells in 
mouse tissue. Plasma cells can be identified by co-staining with anti-
mouse CD138 or alternatively MECA79 staining of HEV can be positively 
identified by morphology or co-staining with a pan-EC marker. 
6. Either Tris/EDTA or Sodium citrate antigen retrieval methods are both 
suitable for detecting HEV in paraffin tissue sections. The choice of 
antigen retrieval is determined by other antibodies used to sequentially 
stain tissue sections. 
7. Hydrogen peroxide/methanol will quench endogenous peroxidase that 
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would otherwise react with the HRP substrate (e.g. DAB) resulting in 
undesirable background. Some proteins may be sensitive to methanol or 
hydrogen peroxide treatment and may reduce staining of the antigen, in 
this case quenching with hydrogen peroxide/methanol may be performed 
after the primary antibody incubation step or alternatively a commercial 
blocking reagent such as Bloxall may used. 
8. It is difficult to distinguish by eye two colocalized stains on a single 
structure or cell by immunohistochemistry e.g. MECA-79 and an EC 
marker. If this is required immunofluorescence is recommended. However, 
spatially separated antigens can be detected by immunohistochemistry. 
9. Light staining with Haematoxylin for 10-20 sec is usually sufficient. 
However, if sections are stained sequentially with multiple antibodies, it 
may be unnecessary to counterstain with Haematoxylin since the antibody 
staining might be obscured. 
10. Each mouse receives 5-10 x 106 labelled donor T cells and two groups of 
5 mice are required per experiment, one group receiving naïve T cells 
pretreated with control antibody and the second pretreated with anti-L-
selectin antibody to inhibit binding of naïve T cells to HEV.  The total 
number of naïve T cells per experiment is therefore 50-100 x 106 T cells.  
The yield of T cells is 30-50 x 106 cells per spleen so 2-3 donor mice will 
provide sufficient T cells for each experiment. If donor mice are limiting, T 
cells can be isolated from peripheral (axillary, brachial and inguinal) and 
mesenteric LN and pooled with splenic T cells.  
11.  Dissecting instruments sterilized by autoclaving in sealed bags or by 
submerging in 70% alcohol. 
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12. We have used kits for isolating T cells and CD8+ T cells from Miltenyi 
Biotec and Stem Cell technologies. 
13. We have used carboxyfluorescein diacetate-succinimidyl ester (CFSE, 
Molecular Probes) 5-(and 6)-([{4-chloromethyl}benzoyl]amino) 
tetramethylrhodamine (CMTMR; Cell Tracker Orange; Molecular probes), 
PKH26 (Molecular Probes) or SNARFJ-1 dye (Molecular Probes) to label 
naïve T cells for short-term homing of wildtype L-selectin expressing T 
cells.  Instead of blocking L-selectin on donor T cells, PNAd-dependent 
homing can be tested by injecting CFSE-labelled naïve T cells into groups 
of recipient mice injected either with 100 µg MECA-79 or 100 µg isotype 
control antibody immediately before donor T cells are injected.  
14. Naïve T cells are CD62L positive and CD44 negative/low. 
15. Where L-selectin deficient T cells are available we have used CMTMR to 
label L-selectin deficient T cells, mixed them 1:1 with CFSE labelled L-
selectin sufficient T cells and injected a total of 20 x 106 cells into a single 
group of experimental mice. In tissues with functional HEV, L-selectin 
sufficient T cells are highly enriched over L-selectin deficient T cells 
(Figure 2). Cell tracker dyes need to be reversed to check for effects of 
cell tracker dyes on T cell recruitment from the bloodstream via HEV in 
wild-type mice (Figure 3B).  
16. To avoid using cell tracker dyes, we have injected unlabeled T cells 
isolated from CD90.2 (Thy.1.2) mice and injected in CD90.1 (Thy.1.1) 
cancer bearing mice and used antibodies to CD90.2 to detect donor T 
cells by flow cytometry and immunohistochemistry. 
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17. To measure recruitment directly from the bloodstream into tissues time 
points of 1-3 hours are preferred since this is before T cells exit 3rd party 
organs such as the spleen or LN. However, the level of T cell recruitment 
into cancerous tissues may be low and longer time points of 24-48 hours 
are required (35) (30).  
18. Collect peripheral LN as positive controls for L-selectin/CD62L dependent 
homing (axillary, brachial, inguinal LN). L-selectin/CD62L-independent 
organs and tissue compartments include mediastinal and mesenteric LN, 
spleen and peripheral blood (Figure 2). 
19. Tissue disaggregation using enzymes may increase the yield of infiltrating 
T cells from fibrotic tissues and cancers over mechanical disaggregation; 
this needs to be determined empirically for each type of tumour.  
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Figure Legends 
Figure 1. HEV can be detected in mouse fibrosarcomas after regulatory T cell 
depletion in FoxP3DTR mice using diptheria toxin. Frozen tumor sections, 
were stained with anti-PNAd (MECA-79, red) + anti-pan-EC (MECA-32, 
green) antibodies (A and B) and anti-PNAd (MECA-79, red) + anti-MAdCAM-1 
(MECA- 367, green) antibodies (C and D). Cell nuclei were counterstained 
with DAPI (blue). Low power images are shown in Panels A and C, and high 
power images of boxed regions are shown in Panels B and D. Scale bars are 
shown in white. 
Figure 2. L-selectin dependent homing of T cells in mice. (A) L-selectin sufficient 
(CD62L+/+) and L-selectin deficient (CD62L-/-) donor T cells were labelled with 
either CFSE or CMTMR and mixed 1:1 (Pre-transfer). 1-3 hours following 
intravenous administration to recipient (A) mice, organs were analysed for 
CD62L+/+ and CD62L-/- T cells and identified as either dependent or 
independent of CD62L/L-selectin. (B) The percentages of CD62L+/+ and 
CD62L-/- T cells pre-transfer and recruited into inguinal (Ing), axillary (Ax) and 
mediastinal (Med) LN, spleen and in peripheral blood (PB) were plotted. T cell 
homing to periphal LN such as inguinal and axillary is L-selectin dependent. In 
contrast, T cell homing to the mucosal-associated mediastinal LN is not 
dependent on L-selectin. HEV are not found in the spleen so not dependent 
on L-selectin for T cell entry. Peripheral blood is analysed to determine 
whether changes to the ratio of T cell populations inside tissues results from a 
change in the ratio in the bloodstream. 
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Figure 3. Localisation of homed T lymphocytes in HEV containing tissues . (A) 
CFSE-labelled naïve T lymphocytes were injected into naïve mice and after 
60 minutes peripheral lymph nodes analysed for infiltrating T cells (green) and 
HEV stained using MECA-79 (red).  Representative image showing CFSE 
labelled (green) T lymphocytes in the process of transmigration and inside 
HEV (arrows) and CFSE labelled T lymphocytes which have completed 
transmigration and outside HEV (white arrows).  Bar, 50 µm. (B) Naïve T 
lymphocytes were split into two and labelled with either CFSE or CMTMR, 
mixed 1:1 and injected into naïve mice. After 60 minutes, peripheral lymph 
nodes were stained for HEV using MECA-79 and the ratio of CFSE (green) to 
CMTMR (orange) T cells inside HEV (white arrows) and outside HEV 
(arrowheads) determined.   
Table 1. Antibodies used for immunofluorescence staining and flow cytometry.  
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Antigen Conjugate Clone Isotype Company Working 
concentratio
n ( g/mL) 
Primary antibodies for immunolabeling frozen sections 
PNAd Purified MECA-79 Rat IgM,  Biolegend 2.5 
Pan endothelial 
cell (pan-EC) 
Biotinylate
d 
MECA-32 Rat IgG2a,  
Biolegend 
2 
MAdCAM-1 Biotinylate
d 
MECA-367 Rat IgG2a,  Biolegend 2 
CD3 Purified 
- 
Rabbit polyclonal DAKO 2 
CD45R/B220 Biotinylate
d 
RA3-6B2 Rat IgG2a,  Biolegend 2 
Follicular 
dendritic cell 
(FDC) 
Purified FDC-M1 Rat IgG2c,  BD 
Biosciences 
2 
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Secondary antibodies/reagents for immunolabeling frozen sections 
Anti-rat IgM 
Alexa 
Fluor 594 - Goat polyclonal Invitrogen 1 
Streptavidin Alexa Fluor 488 - - Invitrogen 1 
Streptavidin Alexa Fluor 647 - - Invitrogen 1 
Anti-rabbit Alexa Fluor 594 - Goat polyclonal Invitrogen 
1 
Anti-rat IgG2c Alexa Fluor FITC 
MARG2c-5 Mouse IgG2a Invitrogen 1 
Isotype control antibodies for immunolabeling frozen sections 
Rat IgM  Purified RTK2118 Rat IgM  Biolegend 2 
Rat IgG2a,  Biotinylated RTK2758 Rat IgG2a,  Biolegend 2 
Rabbit polyclonal Purified - Rabbit polyclonal Abcam 2 
Rat IgG2c,  Purified RTK4174 Rat IgG2c,  Biolegend 2 
Primary antibodies for immunolabeling paraffin sections 
PNAd Purified MECA-79 Rat IgM,  Biolegend 2.5 
CD45R/B220 Purified RA3-6B2 Rat IgG2a,  Biolegend 2 
CD3 Purified - Rabbit polyclonal DAKO 2 
Secondary reagents for immunolabeling paraffin sections 
Immpress anti-rat HRP - Goat Vector  - 
Immpress anti-
rabbit HRP - Horse Vector  - 
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Isotype control antibodies for immunolabeling paraffin sections 
Rat IgM  Purified RTK2118 Rat IgM  Biolegend 2 
Rat IgG2a,  Purified RTK2758 Rat IgG2a,  Biolegend 2 
Rabbit polyclonal Purified - Rabbit polyclonal Abcam 2 
Primary antibodies for flow cytometry of T lymphocytes 
CD62L/L-selectin PE MEL-14 Rat IgG2a Biolegend 0.2 
TCR  FITC H57-597 Armenian Hamster IgG 
BD 
Pharmingen 0.2 
CD44 APC-Cy7 IM7 Rat IgG2b Biolegend 0.2 
 
 
